THOUSAND OAKS, Calif., Oct. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2025 financial results on Tuesday, November 4, 2025, after the close of ...
Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...
Amgen (AMGN) stock climbs as MariTide GLP-1 trials demonstrate nearly 20% weight loss. Truist raises price target to $325 ...
THOUSAND OAKS, Calif., Feb. 13, 2026 /PRNewswire/ -- Amgen (AMGN) will present at Citi's 2026 Virtual Oncology Leadership Summit at 12:15 p.m. PT on Wednesday, Feb. 18, 2026. Jean-Charles Soria, ...
THOUSAND OAKS, Calif., March 5, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference at 9:20 a.m. ET on Wednesday, March 11, 2026. Peter ...
Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...
THOUSAND OAKS, Calif., Jan. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 3, 2026, after ...
Clinical Trials Arena on MSN
Amgen reports positive Phase III findings for subcutaneous Tepezza trial
The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.
THOUSAND OAKS, Calif., Feb. 24, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 46th Annual TD Cowen Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026. Kave Niksefat, senior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results